Human CD39hi regulatory T cells present stronger stability and function under inflammatory conditions

Cellular and Molecular Immunology

Volumn 14, Issue 6, 2017, Pages 521-528

  Gu, Jian ^a   Ni, Xuhao ^a   Pan, Xiongxiong ^a   Lu, Hao ^a   Lu, Yunjie ^a,b   Zhao, Jie ^a   Zheng, Song Guo ^c   Hippen, Keli L ^b   Wang, Xuehao ^a   Lu, Ling ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MINNESOTA   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

CD39; stability; Tregs; xeno GVHD

Indexed keywords

CD39 ANTIGEN; FORKHEAD BOX PROTEIN 3; FORKHEAD TRANSCRIPTION FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN RECEPTOR; STAT1 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; APYRASE; FOXP3 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; CD39 HI REGULATORY T LYMPHOCYTE; CD39 LOW REGULATORY T LYMPHOCYTE; CD4+ CD39 HI REGULATORY T LYMPHOCYTE; CD4+ CD39 LOW REGULATORY T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL SELECTION; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN STABILITY; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TRANSCRIPTION INITIATION; XENOGRAFT; ANIMAL; AUTOIMMUNITY; CELL CULTURE; GENETICS; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; INFLAMMATION; METABOLISM; SCID MOUSE; STEM CELL TRANSPLANTATION;

ANIMALS; ANTIGENS, CD; APYRASE; AUTOIMMUNITY; CELLS, CULTURED; DNA METHYLATION; FORKHEAD TRANSCRIPTION FACTORS; GRAFT VS HOST DISEASE; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; MICE; MICE, SCID; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TRANSPLANTATION, HETEROLOGOUS;

EID: 85020419074     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2016.30     Document Type: Article

References (32)

1. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic selftolerance maintained by activated T cells expressing IL-2 receptor alphachains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164.
2. Li Z, Li D, Tsun A, Li B. FOXP3+ regulatory T cells and their functional regulation. Cell Mol Immunol 2015; 12: 558-565.
3. Kasagi S, Zhang P, Che L, Abbatiello B, Maruyama T, Nakatsukasa H et al. In vivo-generated antigen-specific regulatory T cells treat autoimmunity without compromising antibacterial immune response. Sci Transl Med 2014; 6: 241ra78.
4. Kong N, Lan Q, Chen M, Zheng T, Su W, Wang J et al. Induced T regulatory cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis better than natural T regulatory cells. Ann Rheum Dis 2012; 2012: 6.
5. Ganguly S, Ross DB, Panoskaltsis-Mortari A, Kanakry CG, Blazar BR, Levy RB et al. Donor CD4+ Foxp3+ regulatory T cells are necessary for post-transplantation cyclophosphamide-mediated protection against GVHD in mice. Blood 2014; 124: 2131-2141.
6. Sawant DV, Vignali DA. Once a Treg, always a Treg? Immunol Rev 2014; 259: 173-191.
7. Della Latta V, Cabiati M, Rocchiccioli S, Del Ry S, Morales MA. The role of the adenosinergic system in lung fibrosis. Pharmacol Res 2013; 76: 82-89.
8. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-1265.
9. Lu L, Lan Q, Li Z, Zhou X, Gu J, Li Q et al. Critical role of all-trans retinoic acid in stabilizing human natural regulatory T cells under inflammatory conditions. Proc Natl Acad Sci USA 2014; 111: E3432-E3440.
10. Zhou X, Kong N, Wang J, Fan H, Zou H, Horwitz D et al. Cutting edge: all-trans retinoic acid sustains the stability and function of natural regulatory T cells in an inflammatory milieu. J Immunol 2010; 185: 2675-2679.
11. Sawa S, Kamimura D, Jin GH, Morikawa H, Kamon H, Nishihara M et al. Autoimmune arthritis associated with mutated interleukin (IL)-6 receptor gp130 is driven by STAT3/IL-7-dependent homeostatic proliferation of CD4+ T cells. J Exp Med 2006; 203: 1459-1470.
12. Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007; 5: e38.
13. Sauzullo I, Mastroianni CM, Mengoni F, Ermocida A, Mascia C, Salotti A et al. Long-term IFN-gamma and IL-2 response for detection of latent tuberculosis infection in healthcare workers with discordant immunologic results. J Immunol Methods 2014; 414: 51-57.
14. Mizui M, Koga T, Lieberman LA, Beltran J, Yoshida N, Johnson MC et al. IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8-IL-17-producing T cells. J Immunol 2014; 193: 2168-2177.
15. Zhang P, Tey SK, Koyama M, Kuns RD, Olver SD, Lineburg KE et al. Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo. J Immunol 2013; 191: 5291-5303.
16. Zhang X, Wei HX, Rui S, Wei H, Tian Z. Opposite effects of high and low doses of interleukin-2 on T cell-mediated hepatitis in mice (interleukin-2 on hepatitis). Hepatol Int 2010; 4: 641-648.
17. Makrilakis K, Fragiadaki K, Smith J, Sfikakis PP, Kitas GD. Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade. Clin Rheumatol 2014; 34: 419-427.
18. Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med 2014; 20: 62-68.
19. Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, Grainger JR et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 2011; 12: 247-254.
20. Park BV, Pan F. The role of nuclear receptors in regulation of Th17/Treg biology and its implications for diseases. Cell Mol Immunol 2015; 12: 533-542.
21. Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008; 28: 687-697.
22. Leal DB, Streher CA, Bertoncheli Cde M, Carli LF, Leal CA, da Silva JE et al. HIV infection is associated with increased NTPDase activity that correlates with CD39-positive lymphocytes. Biochim Biophys Acta 2005; 1746: 6.
23. Nikolova M, Carriere M, Jenabian MA, Limou S, Younas M, Kok A et al. CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog 2011; 7: e1002110.
24. Wang Y, Begum-Haque S, Telesford KM, Ochoa-Reparaz J, Christy M, Kasper EJ et al. A commensal bacterial product elicits and modulates migratory capacity of CD39 CD4 T regulatory subsets in the suppression of neuroinflammation. Gut Microbes 2014; 5: 552-561.
25. Schuler PJ, Saze Z, Hong CS, Muller L, Gillespie DG, Cheng D et al. Human CD4(+) CD39(+) regulatory T cells produce adenosine upon coexpression of surface CD73 or contact with CD73(+) exosomes or CD73 (+) cells. Clin Exp Immunol 2014; 177: 13.
26. Otsuka A, Hanakawa S, Miyachi Y, Kabashima K. CD39: a new surface marker of mouse regulatory gammadelta T cells. J Allergy Clin Immunol 2013; 132: 1448-1451.
27. Mandapathil M, Szczepanski MJ, Szajnik M, Ren J, Jackson EK, Johnson JT et al. Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem 2010; 285: 27571-27580.
28. Thiolat A, Semerano L, Pers YM, Biton J, Lemeiter D, Portales P et al. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheumatol 2014; 66: 273-283.
29. Ryzhov SV, Pickup MW, Chytil A, Gorska AE, Zhang Q, Owens P et al. Role of TGF-beta signaling in generation of CD39+CD73+ myeloid cells in tumors. J Immunol 2014; 193: 3155-3164.
30. Lu Y, Wang J, Gu J, Lu H, Li X, Qian X et al. Rapamycin regulates iTreg function through CD39 and Runx1 pathways. J Immunol Res 2014; 2014: 989434.
31. Akimova T, Kamath BM, Goebel JW, Meyers KE, Rand EB, Hawkins A et al. Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients. Am J Transplant 2012; 12: 3449-3461.
32. Lu Y, Wang X, Gu J, Lu H, Zhang F, Li X et al. iTreg induced from CD39 (+) naive T cells demonstrate enhanced proliferate and suppressive ability. Int Immunopharmacol 2015; 28: 925-930.